Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid.

When cancer cells are present in the CSF, the molecular profiling from the cell pellets is relevant, as it can detect supplemental or different mutations compared to a previous analysis of the primitive tumour or plasma cell-free DNA and allows the adaptation of the treatment strategy.